| Literature DB >> 35719959 |
Zhi-Qiang Lin1,2, Chi Ma1,3, Wen-Zhuo Cao1,3, Zhen Ning1,3, Guang Tan1,3.
Abstract
Objective: This study evaluated the prognostic significance of preoperative neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and tumor-infiltrating lymphocytes (TILs), and whether these preoperative blood inflammatory indicators were associated with TILs in hilar cholangiocarcinoma (HCCA).Entities:
Keywords: LMR; NLR; PLR; hilar cholangiocarcinoma; tumor-infiltrating lymphocytes
Year: 2022 PMID: 35719959 PMCID: PMC9203898 DOI: 10.3389/fonc.2022.908907
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Baseline characteristics.
| Variables | No. of patients (%) |
|---|---|
| Age(year) | |
| <60 | 36 (47.4%) |
| ≥60 | 40 (52.6%) |
| Gender | |
| Male | 41 (53.7%) |
| Female | 35 (46.1%) |
| Tumor stage | |
| T1-T2 | 32 (42.1%) |
| T3-T4 | 44 (57.9%) |
| Lymph node metastasis | |
| No | 51 (67.1%) |
| Yes | 25 (32.9%) |
| Liver invasion | |
| No | 63 (82.9%) |
| Yes | 13 (17.1%) |
| Portal vein invasion | |
| No | 37 (48.7%) |
| Yes | 39 (51.3%) |
| Neural invasion | |
| No | 22 (28.9%) |
| Yes | 54 (71.1%) |
| Bismuth-Coretre type | |
| I-II | 33 (43.4%) |
| III-IV | 43 (56.6%) |
| Tumor differentiation | |
| Moderate/poor | 65 (85.5%) |
| well | 11 (14.5%) |
| Tumor size (cm) | |
| <3 | 50 (64.9%) |
| ≥3 | 26 (33.8%) |
| Total bilirubin (μmol/L) | |
| <34.2 | 13 (17.1%) |
| ≥34.2 | 63 (82.9%) |
Characteristics of the patients grouped immune cells and peripheral blood.
| Variables | NLR | PLR | LMR | CD3 | CD4 | CD8 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <2.00 | ≥2.00 | <117.60 | ≥117.60 | <4.02 | ≥4.02 | <93.5 | ≥93.5 | <56.5 | ≥56.5 | <54.5 | ≥54.5 | |||||||
| Age (year) | ||||||||||||||||||
| <60 | 20 | 16 | 0.001 | 19 | 17 | 0.370 | 20 | 16 | 0.175 | 16 | 20 | 0.358 | 19 | 17 | 0.646 | 22 | 14 | 0.066 |
| ≥60 | 7 | 33 | 17 | 23 | 16 | 24 | 22 | 18 | 19 | 21 | 16 | 24 | ||||||
| Gender | ||||||||||||||||||
| Male | 18 | 23 | 0.512 | 21 | 20 | 0.467 | 18 | 23 | 0.512 | 18 | 23 | 0.250 | 21 | 20 | 0.818 | 23 | 18 | 0.198 |
| Female | 9 | 26 | 15 | 20 | 18 | 17 | 20 | 15 | 17 | 18 | 15 | 20 | ||||||
| Tumor stage | ||||||||||||||||||
| T1-T2 | 16 | 16 | 0.025 | 17 | 15 | 0.391 | 5 | 27 | 0.003 | 9 | 23 | 0.001 | 18 | 14 | 0.691 | 9 | 23 | 0.001 |
| T3-T4 | 11 | 33 | 19 | 25 | 31 | 13 | 29 | 15 | 20 | 24 | 29 | 15 | ||||||
| Lymph node metastasis | ||||||||||||||||||
| No | 18 | 33 | 0.952 | 23 | 28 | 0.571 | 23 | 28 | 0.571 | 19 | 32 | 0.002 | 26 | 25 | 0.807 | 18 | 33 | 0.001 |
| Yes | 9 | 16 | 13 | 12 | 13 | 12 | 19 | 6 | 12 | 13 | 20 | 5 | ||||||
| Bismuth-Coretre type | ||||||||||||||||||
| I-II | 16 | 17 | 0.039 | 17 | 16 | 0.526 | 16 | 17 | 0.864 | 11 | 22 | 0.011 | 13 | 20 | 0.105 | 12 | 21 | 0.025 |
| III-IV | 11 | 32 | 19 | 24 | 20 | 23 | 27 | 16 | 25 | 18 | 26 | 17 | ||||||
| Tumor differentiation | ||||||||||||||||||
| Moderate/poor | 23 | 42 | 0.949 | 34 | 31 | 0.036 | 30 | 35 | 0.606 | 33 | 32 | 0.744 | 31 | 34 | 0.328 | 33 | 32 | 0.744 |
| well | 4 | 7 | 2 | 9 | 6 | 5 | 5 | 6 | 7 | 4 | 5 | 6 | ||||||
| Tumor size (cm) | ||||||||||||||||||
| <3 | 19 | 31 | 0.532 | 22 | 28 | 0.015 | 26 | 24 | 0.262 | 26 | 24 | 0.472 | 23 | 27 | 0.231 | 25 | 25 | 0.688 |
| ≥3 | 8 | 18 | 16 | 10 | 10 | 16 | 12 | 14 | 16 | 10 | 13 | 13 | ||||||
| Liver invasion | ||||||||||||||||||
| No | 22 | 41 | 1.000 | 29 | 34 | 0.607 | 30 | 33 | 0.923 | 33 | 30 | 0.361 | 29 | 34 | 0.128 | 29 | 34 | 0.128 |
| Yes | 5 | 8 | 7 | 6 | 6 | 7 | 5 | 8 | 9 | 4 | 9 | 4 | ||||||
| Neural invasion | ||||||||||||||||||
| No | 8 | 14 | 0.922 | 8 | 14 | 0.220 | 13 | 9 | 0.191 | 8 | 14 | 0.129 | 12 | 10 | 0.613 | 7 | 15 | 0.052 |
| Yes | 19 | 35 | 28 | 26 | 23 | 31 | 30 | 24 | 26 | 28 | 31 | 23 | ||||||
| Portal vein invasion | ||||||||||||||||||
| No | 16 | 21 | 0.171 | 17 | 20 | 0.809 | 13 | 24 | 0.037 | 11 | 26 | 0.001 | 18 | 19 | 0.818 | 12 | 25 | 0.002 |
| Yes | 11 | 28 | 19 | 20 | 23 | 16 | 27 | 12 | 20 | 19 | 26 | 13 | ||||||
| CEA (ng/ml) | ||||||||||||||||||
| <5.0 | 22 | 43 | 0.457 | 30 | 35 | 0.486 | 34 | 31 | 0.036 | 32 | 33 | 0.744 | 32 | 33 | 0.744 | 34 | 31 | 0.328 |
| ≥5.0 | 5 | 6 | 6 | 5 | 2 | 9 | 6 | 5 | 6 | 5 | 4 | 7 | ||||||
| CA19-9 (U/ml) | ||||||||||||||||||
| <37 | 13 | 12 | 0.035 | 14 | 11 | 0.291 | 16 | 9 | 0.052 | 8 | 17 | 0.028 | 14 | 11 | 0.464 | 7 | 18 | 0.007 |
| ≥37 | 14 | 37 | 22 | 29 | 20 | 31 | 30 | 21 | 24 | 27 | 31 | 20 | ||||||
| Total bilirubin(μmol/L) | ||||||||||||||||||
| <34.2 | 4 | 9 | 0.693 | 7 | 6 | 0.546 | 8 | 5 | 0.261 | 3 | 10 | 0.033 | 9 | 4 | 0.128 | 7 | 6 | 0.761 |
| ≥34.2 | 23 | 40 | 29 | 34 | 28 | 35 | 35 | 28 | 29 | 34 | 31 | 32 | ||||||
CEA, carcinoembryonic antigen; CA, 19-9 cancer antigen 19-9; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; LMR, lymphocyte monocyte ratio.
Figure 1Representative images of immunohistochemical features of high-level and low-level tumor-infiltrating inflammatory cells in hilar cholangiocarcinoma: CD3+T cells, CD4+ T cells and CD8+T cells. (×400 magnification).
Figure 2Kaplan-Meier analysis for OS in patients with hilar cholangiocarcinoma.(A) OS for patients with different levels of NMR. (B) OS for patients with different levels of LMR. (C) OS for patients with different levels of PLR. (D) OS for patients with different levels of tumor-infiltrating CD3+T cells infiltration. (E) OS for patients with different levels of tumor-infiltrating CD8+T cells infiltration. (F) OS for patients with different levels of tumor-infiltrating CD4+T cells infiltration.
Figure 3Correlations between systemic inflammation markers and density of immune cells in the tumor microenvironment. (A) Correlation between NLR and levels of CD3+ T cells infiltration. (B) Correlation between PLR and levels of CD3+ T cells infiltration. (C) Correlation between LMR and levels of CD3+ T cells infiltration. (D) Correlation between NLR and levels of CD4+ T cells infiltration. (E) Correlation between PLR and levels of CD4+ T cells infiltration. (F) Correlation between LMR and levels of CD4+ T cells infiltration. (G) Correlation between NLR and levels of CD8+ T cells infiltration. (H) Correlation between PLR and levels of CD8+ T cells infiltration. (I) Correlation between LMR and levels of CD8+ T cells infiltration.
Univariate analysis for overall survival.
| Variables | 3-year OS(%) | 95% for CI | χ2 | |
|---|---|---|---|---|
| Age (year) | ||||
| <60 | 36.8 | 20.786-36.240 | 0.081 | 0.776 |
| ≥60 | 26.3 | 24.692-38.178 | ||
| Gender | ||||
| Male | 22.0 | 19.078-31.941 | 5.712 | 0.017 |
| Female | 37.1 | 29.449-49.265 | ||
| Tumor stage | ||||
| T1-T2 | 56.3 | 39.720-62.207 | 29.136 | <0.001 |
| T3-T4 | 13.6 | 15.708-24.337 | ||
| Lymph node metastasis | ||||
| No | 36.8 | 30.258-44.609 | 34.197 | <0.001 |
| Yes | 12.0 | 12.201-22.199 | ||
| Bismuth-Coretre type | ||||
| I-II | 48.5 | 34.778-56.871 | 33.125 | <0.001 |
| III-IV | 14.0 | 17.356-27.388 | ||
| Tumor differentiation | ||||
| Moderate/poor | 27.4 | 26.219-61.963 | 2.547 | 0.110 |
| well | 36.4 | 23.361-34.048 | ||
| Tumor size (cm) | ||||
| <3 | 32.1 | 26.310-43.763 | 0.501 | 0.479 |
| ≥3 | 22.2 | 21.407-35.497 | ||
| Liver invation | ||||
| No | 31.7 | 26.793-40.869 | 1.223 | 0.269 |
| Yes | 15.4 | 17.938-31.447 | ||
| Neural invasion | ||||
| No | 53.8 | 30.977-54.750 | 7.075 | 0.008 |
| Yes | 18.5 | 20.652-32.040 | ||
| Portal vein invasion | ||||
| No | 48.6 | 36.354-57.150 | 29.132 | <0.001 |
| Yes | 10.3 | 15.349-24.754 | ||
| Total bilirubin (μmol/L) | ||||
| <34.2 | 46.2 | 28.857-56.528 | 4.334 | 0.037 |
| ≥34.2 | 25.4 | 22.806-34.057 | ||
| CEA(ng/ml) | ||||
| <5.0 | 29.2 | 25.165-37.390 | 0.113 | 0.737 |
| ≥5.0 | 27.3 | 17.059-35.487 | ||
| CA19-9(U/ml) | ||||
| <37 | 52.0 | 33.711-57.617 | 10.674 | <0.001 |
| ≥37 | 17.6 | 19.344-30.094 | ||
| NLR | ||||
| <2.00 | 51.9 | 39.065-55.414 | 21.352 | 0.010 |
| ≥2.00 | 0.0 | 11.451-15.578 | ||
| PLR | ||||
| <117.60 | 44.0 | 27.703-49.363 | 2.660 | 0.103 |
| ≥117.60 | 21.2 | 21.734-34.252 | ||
| LMR | ||||
| <4.02 | 9.65 | 10.025-20.451 | 30.857 | <0.001 |
| ≥4.02 | 36.0 | 30.261-44.054 | ||
| CD3 | ||||
| <93.5 | 0.0 | 11.934-15.172 | 78.301 | <0.001 |
| ≥93.5 | 57.4 | 41.477-58.111 | ||
| CD4 | ||||
| <56.5 | 31.1 | 24.054-40.111 | 0.087 | 0.767 |
| ≥56.5 | 26.3 | 22.931-40.332 | ||
| CD8 | ||||
| <54.5 | 5.4 | 25.824-37.727 | 25.464 | 0.015 |
| ≥54.5 | 52.4 |
CEA, carcinoembryonic antigen; CA, 19-9 cancer antigen 19-9; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; LMR, lymphocyte monocyte ratio; OS, overall survival; CI, confidence interval.
Multivariable analysis for overall survival.
| Variables | β | SE | Wald | HR | 95.0% for CI | |
|---|---|---|---|---|---|---|
| Gender | -0.113 | 0.366 | 0.093 | 0.761 | 0.893 | 0.432-1.846 |
| Tumor stage | 2.914 | 0.943 | 20.521 | <0.001 | 18.428 | 5.223-65.012 |
| Lymph node metastasis | 1.118 | 0.862 | 7.099 | 0.008 | 2.769 | 1.309-5.856 |
| Bismuth-Coretre type | 0.698 | 0.677 | 0.525 | 0.509 | 1.384 | 0.538-2.762 |
| Neural invasion | 0.811 | 0.735 | 0.725 | 0.355 | 2.057 | 1.098-5.042 |
| Portal vein invasion | 0.437 | 0.440 | 0.016 | 0.700 | 1.070 | 0.371-3.083 |
| Total bilirubin | 0.682 | 0.661 | 0.436 | 0.636 | 1.219 | 0.423-5.656 |
| CA19-9 | 1.184 | 0.880 | 7.728 | 0.005 | 2.957 | 1.377-6.350 |
| NLR | 0.546 | 0.535 | 0.307 | 0.687 | 1.147 | 0.455-4.404 |
| LMR | -1.708 | 0.889 | 19.271 | <0.001 | 0.181 | 0.085-0.389 |
LMR, lymphocyte monocyte ratio; HR, hazard ratio; CI, confidence interval.
Figure 4Kaplan-Meier analysis for OS in patients with hilar cholangiocarcinoma. Double positive is LMR≥4.02 and CD3≥93.5, Single positive is LMR≥4.02 or CD3≥93.5, Double negative is LMR<4.02 and CD3<93.5.